Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
09:44am, Friday, 28'th Mar 2025
AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
02:00am, Friday, 28'th Mar 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
12:55pm, Wednesday, 26'th Mar 2025
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
03:10am, Wednesday, 26'th Mar 2025
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
02:00am, Wednesday, 26'th Mar 2025
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
09:00am, Tuesday, 25'th Mar 2025
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
02:00am, Tuesday, 25'th Mar 2025
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to bo
Press Release: Availability of the Q1 2025 Aide mémoire
02:30am, Monday, 24'th Mar 2025
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First q
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
01:30pm, Thursday, 20'th Mar 2025
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Sanofi to acquire Dren Bio's immunology unit
02:29am, Thursday, 20'th Mar 2025
Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
02:00am, Thursday, 20'th Mar 2025
Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
02:18pm, Friday, 14'th Mar 2025
BRIDGEWATER, N.J. , March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturi
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
10:12am, Wednesday, 12'th Mar 2025
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often p
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
08:55am, Tuesday, 11'th Mar 2025
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
01:00pm, Saturday, 08'th Mar 2025
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant
